Marrades R M, Alonso J, Roca J, González de Suso J M, Campistol J M, Barberá J A, Diaz O, Torregrosa J V, Masclans J R, Rodríguez-Roisin R, Wagner P D
Servei de Pneumologia i Al.lèrgia respiratòria, Hospital Clínic, Universitat de Barcelona, Spain.
J Clin Invest. 1996 May 1;97(9):2101-10. doi: 10.1172/JCI118647.
After erythropoietin (rHuEPO) therapy, patients with chronic renal failure (CRF) do not improve peak O2 uptake (VO2 peak) as much as expected from the rise in hemoglobin concentration ([Hb]). In a companion study, we explain this phenomenon by the concurrent effects of fall in muscle blood flow after rHuEPO and abnormal capillary O2 conductance observed in CRF patients. The latter is likely associated with a poor muscle microcirculatory network and capillary-myofiber dissociation due to uremic myopathy. Herein, cellular bioenergetics and its relationships with muscle O2 transport, before and after rHuEPO therapy, were examined in eight CRF patients (27 +/- 7.3 [SD] yr) studied pre- and post-rHuEPO ([Hb] = 7.8 +/- 0.7 vs. 11.7 +/- 0.7 g x dl-1) during an incremental cycling exercise protocol. Eight healthy sedentary subjects (26 +/- 3.1 yr) served as controls. We hypothesize that uremic myopathy provokes a cytosolic dysfunction but mitochondrial oxidative capacity is not abnormal. 31P-nuclear magnetic resonance spectra (31P-MRS) from the vastus medialis were obtained throughout the exercise protocol consisting of periods of 2 min exercise (at 1.67 Hz) at increasing work-loads interspersed by resting periods of 2.5 min. On a different day, after an identical exercise protocol, arterial and femoral venous blood gas data were obtained together with simultaneous measurements of femoral venous blood flow (Qleg) to calculate O2 delivery (QO2leg) and O2 uptake (VO2leg). Baseline resting [phosphocreatine] to [inorganic phosphate] ratio ([PCr]/[Pi]) did not change after rHuEPO (8.9 +/- 1.2 vs. 8.8 +/- 1.2, respectively), but it was significantly lower than in controls (10.9 +/- 1.5) (P = 0.01 each). At a given submaximal or peak VO2leg, no effects of rHuEPO were seen on cellular bioenergetics ([PCr]/[Pi] ratio, %[PCr] consumption halftime of [PCr] recovery after exercise), nor in intracellular pH (pHi). The post-rHuEPO bioenergetic status and pHi, at a given VO2leg, were below those observed in the control group. However, at a given pHi, no differences in 31P-MRS data were detected between post-rHuEPO and controls. After rHuEPO, at peak VO2, Qleg fell 20% (P < 0.04), limiting the change in QO2leg to 17%, a value that did not reach statistical significance. The corresponding O2 extraction ratio decreased from 73 +/- 4% to 68 +/- 8.2% (P < 0.03). These changes indicate that maximal O2 flow from microcirculation to mitochondria did not increase despite the 50% increase in [Hb] and explain how peak VO2leg and cellular bioenergetics (31P-MRS) did not change after rHuEPO. Differences in pHi, possibly due to lactate differences, between post-rHeEPO and controls appear to be a key factor in the abnormal muscle cell bioenergetics during exercise observed in CRF patients.
在接受促红细胞生成素(rHuEPO)治疗后,慢性肾衰竭(CRF)患者的峰值摄氧量(VO2峰值)并未像血红蛋白浓度([Hb])升高所预期的那样得到改善。在一项配套研究中,我们通过rHuEPO治疗后肌肉血流量下降以及CRF患者中观察到的异常毛细血管氧传导的共同作用来解释这一现象。后者可能与尿毒症性肌病导致的肌肉微循环网络不良和毛细血管 - 肌纤维解离有关。在此,我们在递增式自行车运动方案期间,对8例CRF患者(年龄27±7.3[标准差]岁)进行了rHuEPO治疗前后的细胞生物能量学及其与肌肉氧运输关系的研究,这些患者在治疗前和治疗后([Hb]分别为7.8±0.7和11.7±0.7 g×dl-1)。8名健康久坐的受试者(年龄26±3.1岁)作为对照。我们假设尿毒症性肌病会引发胞质功能障碍,但线粒体氧化能力并无异常。在整个运动方案中,包括在递增工作负荷下进行2分钟运动(频率1.67 Hz)并穿插2.5分钟休息期,获取股内侧肌的31P - 核磁共振波谱(31P - MRS)。在不同的一天,经过相同的运动方案后,获取动脉和股静脉血气数据,并同时测量股静脉血流量(Qleg)以计算氧输送量(QO2leg)和摄氧量(VO2leg)。rHuEPO治疗后,静息状态下的基线磷酸肌酸与无机磷酸比值([PCr]/[Pi])没有变化(分别为8.9±1.2和8.8±1.2),但显著低于对照组(10.9±1.5)(P值均为0.01)。在给定的次最大或峰值VO2leg时,rHuEPO对细胞生物能量学([PCr]/[Pi]比值、[PCr]消耗半衰期、运动后[PCr]恢复情况)以及细胞内pH值(pHi)均无影响。在给定的VO2leg时,rHuEPO治疗后的生物能量状态和pHi低于对照组观察到的值。然而,在给定的pHi时,rHuEPO治疗后与对照组之间在31P - MRS数据上未检测到差异。rHuEPO治疗后,在VO2峰值时,Qleg下降了20%(P < 0.04),使得QO2leg的变化限制在17%,该值未达到统计学显著性。相应的氧摄取率从73±4%降至68±8.2%(P < 0.03)。这些变化表明,尽管[Hb]增加了50%,但从微循环到线粒体的最大氧流量并未增加,这解释了rHuEPO治疗后VO2leg峰值和细胞生物能量学(31P - MRS)为何没有变化。rHuEPO治疗后与对照组之间pHi的差异,可能是由于乳酸差异,似乎是CRF患者运动期间异常肌肉细胞生物能量学的一个关键因素。